Aptose Biosciences Inc (NASDAQ:APTO) does about 561.64K shares in volume on a normal day but saw 12043839 shares change hands in the recent trading day. The company now has a market cap of 4.10M USD. Its current market price is $0.19, marking a decrease of -22.13% compared to the previous close of $0.24. The 52 week high reached by this stock is $2.91 whilst the lowest price level in 52 weeks is $0.23.
Aptose Biosciences Inc (APTO) has a 20-day trading average at $0.3590 and the current price is -93.47% off the 52-week high compared with -17.96% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.3753 and its 200-day simple moving average is $0.8835. If we look at the stock’s price movements over the week, volatility stands at 24.52%, which decreases to 10.84% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 19.26 to suggest the stock is oversold.
The consensus objective for the share price is $2.00, suggesting that the stock has a potential upside of 90.5% over the period.
FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on October 19, 2020 when Cantor Fitzgerald initiated the stock to “Overweight” and issued a price target of $10. Maxim Group initiated its price target at $16.
The current price level is -47.07%, -49.38%, and -78.50% away from its SMA20, SMA50, and SMA200 respectively, with the APTO price moving above the 50-day SMA on current market day. Aptose Biosciences Inc (APTO) stock is down -47.94% over the week and -50.65% over the past month. Its price is -92.52% year-to-date and -92.18% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/30/2024, with the company’s earnings per share (EPS) of -1.44 above consensus estimates by 0.34. The company’s next earnings report forecasts estimating quarterly EPS at -0.35 and -1.79 for whole year.
To reach the target analysts have set, the stock logically needs to grow 90.5 percent from here.
Outstanding shares total 19.52M with insiders holding 15.87% of the shares and institutional holders owning 16.69% of the company’s common stock. The company has a return on investment of -3057.22% and return on equity of -694.13%. The beta has a value of 1.14.
